title: Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
abstract: BACKGROUND
  Combinations of gemcitabine-oxaliplatin, gemcitabine-5-fluorouracil (5-FU) and 5-FU-oxaliplatin have synergistic activity and nonoverlapping adverse effect profiles. This trial assessed efficacy and safety of the triple combination gemcitabine-oxaliplatin and infusional 5-FU in patients with locally advanced (n=11) or metastatic (n=32) pancreatic adenocarcinoma.
  
  
  METHODS
  A total of 43 eligible patients were treated with intravenous infusions of gemcitabine (900 mg/m2 over 30 min), followed by oxaliplatin (65 mg/m2 over 2 h) and 5-FU (1500 mg/m2 over 24 h) on days 1 and 8 of a 21-day cycle.
  
  
  RESULTS
  Among all 43 patients, the tumor response rate was 19% [95% confidence interval 7% to 30%]. Nine patients were nonassessable for response because they did not complete the first two cycles of chemotherapy due to rapid disease progression, early death or treatment refusal. One patient was lost to follow-up. Median time to progression and overall survival were 5.7 and 7.5 months. Principal grade III/IV toxic effects were leucopenia in 11 (2%), thrombocytopenia in 13 (2%), nausea in 13 (0%), anorexia 16 (7%) and sensory neuropathy in 18 (0%) of patients. Unexpected cardiotoxicity was observed in this trial.
  
  
  CONCLUSIONS
  Response rates and survival of the three-drug combination compare favorably with single-agent gemcitabine, but do not exceed results for doublets.
authors.affiliation: First Department of Medicine, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany. Electronic address: anna-dorothea.wagner@gmx.de.
authors.forename: A D
authors.initials: AD
authors.lastname: Wagner
authors.affiliation: First Department of Medicine, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
authors.forename: P
authors.initials: P
authors.lastname: Buechner-Steudel
authors.affiliation: First Department of Medicine, Friedrich-Alexander-University Erlangen, Erlangen, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Wein
authors.affiliation: Department of Medicine II, Friedrich-Schiller-University, Jena, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Schmalenberg
authors.affiliation: Department of Medicine II, Friedrich-Schiller-University, Jena, Germany.
authors.forename: U
authors.initials: U
authors.lastname: Lindig
authors.affiliation: First Department of Medicine, Johannes-Gutenberg-University Mainz, Mainz, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Moehler
authors.affiliation: Gastroenterology Practice, Halle (Saale), Germany.
authors.forename: R
authors.initials: R
authors.lastname: Behrens
authors.affiliation: First Department of Medicine, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
authors.forename: G
authors.initials: G
authors.lastname: Kleber
authors.affiliation: Institute of Medical Epidemiology, Biostatistics and Informatics, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
authors.forename: O
authors.initials: O
authors.lastname: Kuss
authors.affiliation: First Department of Medicine, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
authors.forename: W E
authors.initials: WE
authors.lastname: Fleig
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011788:Quality of Life; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003841:Deoxycytidine; D005472:Fluorouracil; D000093542:Gemcitabine